Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633

Gary M. Strauss, James E. Herndon, Michael A. Maddaus, +6

Journal of Clinical Oncology

Randomized Clinical TrialSurgical OncologyIii NsclcMedicineProtocol 9633 +12

Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633

Gary M. Strauss, Justine Herndon, Michael A. Maddaus, +6

Journal of Clinical Oncology

Randomized Clinical TrialSurgical OncologyIii NsclcMedicineProtocol 9633 +12

Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial

Everett E. Vokes, James E. Herndon, Michael J. Kelley, +3

Journal of Clinical Oncology

Radiation MedicineHealth SciencesRadiation TherapyMedicineIdentical Ct/xrt +13

CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC)

Neal Ready, Arkadiusz Z. Dudek, X. F. Wang, +3

Journal of Clinical Oncology

Cancer ManagementPathologyPhase Ii StudyTumor BiologyHematological Malignancy +14

Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines.

Hamid R. Bahadori, Caio Max S. Rocha Lima, M. R. Green, +1

PubMed

Tumor BiologySynergistic EffectOncologyMcf-7 Breast CancerMedicine +10

Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107)

Thierry Jahan, Liufang Gu, X. Wang, +5

Journal of Clinical Oncology

Vascular DiseaseHuman GrowthPathologyMm Express VegfPharmacotherapy +20

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902

Caio Rocha‐Lima, James E. Herndon, Mi-Ji Lee, +4

Annals of Oncology

Phase Ii TrialMedicineMetronomic TherapyPharmacologyPharmacotherapy +4

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234

N. J. Vogelzang, James E. Herndon, Antonius A. Miller, +8

Annals of Oncology

Malignant DiseaseMalignant MesotheliomaMedicinePathologyHigh-dose Paclitaxel +6

Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial

Neal Ready, Pasi A. Jänne, James E. Herndon, +7

Journal of Clinical Oncology

Advanced NsclcRadiation MedicinePhase Ii TrialRadiation TherapyMedicine +12

Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.

Caio Max S. Rocha Lima, John R. Eckardt, Swan Swan Leong, +6

PubMed